Igu-plga-nps nanoparticle and its preparation method and application

A nanoparticle and emulsion technology, applied in nanotechnology, nanotechnology, nanomedicine, etc., can solve the problems of poor clinical results, brain difficulties, and low survival rate, and achieve the goal of promoting cell apoptosis and cell cycle arrest Effect

Active Publication Date: 2021-07-02
SOUTHEAST UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the extremely aggressive and migratory nature of glioma, postoperative recurrence is very common, and the five-year survival rate after surgery is less than 10%.
Although many drug candidates may exhibit significant activity in vitro, there are two main reasons for suboptimal clinical outcomes: (1) drug entry into the brain is difficult due to inability to cross the blood-brain barrier (BBB); (2)90 % of resected tumors recur within 2 cm of the primary site due to the presence of chemoradiation-resistant glioma stem cells (GSCs)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Igu-plga-nps nanoparticle and its preparation method and application
  • Igu-plga-nps nanoparticle and its preparation method and application
  • Igu-plga-nps nanoparticle and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Preparation method of IGU-PLGA-NPs nanoparticles

[0037] Dissolve 100 mg of PLGA in 5 ml of dichloromethane solution, and add 200 μL of 30 μg / mL IGU aqueous solution. The mixture was sonicated to form an emulsion using probe sonication (MicrosonXL 2000, Misonix Inc., Farmingdale, NY) at 20 kHz and 30% amplitude. The emulsion was rapidly mixed with 5 ml of 4% PVA (polyvinyl alcohol solution) and homogenized at 6000 rpm for 30 min. Then 5ml of deionized water was added, stirred at room temperature overnight, and then centrifuged at 17000rpm for 15min to collect nanoparticles (NPs). The PVA in the NPs was washed three times with double distilled water, EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride), NHS (N-hydroxy-succinyl amine; Sigma) and PEI (polyethyleneimine) activation, incubated at 20°C for 2h, washed twice with deionized water, and stored at 4°C for further use.

[0038] Characterization of IGU-PLGA-NPs

[0039] The morphology of PLGA and I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of nano industry, and particularly relates to a kind of IGU-PLGA-NPs nanoparticle and its preparation method and application. IGU-PLGA-NPs is a nanoparticle of IGU wrapped with PLGA; the preparation method comprises the following steps: step 1, PLGA is dissolved in dichloromethane solution, adding IGU aqueous solution, ultrasonically processing the mixture with a probe to form an emulsion; step 2, mixing the emulsion prepared in step 1 with polyvinyl alcohol solution, homogenizing, and then adding deionized water, After stirring overnight, centrifuge to collect nanoparticles; step 3, after washing the nanoparticles prepared in step 2 with double distilled water, use EDC (1-ethyl-3-(3-dimethylaminopropyl) carbon dioxide imine hydrochloride), NHS (N-hydroxy-succinimide; Sigma) and PEI (polyethyleneimine) activation to produce IGU-PLGA-NPs nanoparticles; the IGU-PLGA-NPs can be used to prepare therapeutic Pharmaceutical preparations for malignant glioma.

Description

technical field [0001] The invention belongs to the technical field of nano industry, and in particular relates to an IGU-PLGA-NPs nano particle and a preparation method and application thereof. Background technique [0002] Glioma (GBM) is the most common primary brain tumor arising from the carcinogenesis of glial cells in the brain and spinal cord, with an annual incidence of about 3-8 per 100,000 people. The current treatment methods for glioma mainly include surgery, postoperative resection and radiotherapy, and temozolomide (TMZ) chemotherapy. However, due to the extremely aggressive and migratory nature of brain glioma, postoperative recurrence is very common, and the postoperative five-year survival rate is less than 10%. Although many drug candidates may exhibit significant activity in vitro, there are two main reasons for suboptimal clinical outcomes: (1) drug entry into the brain is difficult due to inability to cross the blood-brain barrier (BBB); (2)90 % of re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/16A61K47/34A61K31/352A61P35/00B82Y5/00B82Y40/00
CPCA61K9/1647A61K31/352A61P35/00B82Y5/00B82Y40/00
Inventor 袁榴娣元尼
Owner SOUTHEAST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap